Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2

Biochemical Pharmacology

Volumn 66, Issue 5, 2003, Pages 801-807

  Yamagami, Hideomi ^a   Nishioka, Tatsuo ^a   Ochiai, Eiji ^a   Fukushima, Kazuyo ^a   Nomura, Masaaki ^a   Kasugai, Shohei ^b   Moritani, Shuzo ^c   Yokogawa, Koichi ^a   Miyamoto, Ken Ichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c FUKUI PREFECTURAL UNIVERSITY   (Japan)

Author keywords

cAMP; Osteoclastogenesis; Phosphodiesterase 4 (PDE4) inhibitor; Prostaglandin E2 (PGE2); XT 611

Indexed keywords

3,4 DIPROPYL 4,5,7,8 TETRAHYDRO 3H IMIDAZO[1,2 I]PURIN 5 ONE; CALCITONIN RECEPTOR; COLONY STIMULATING FACTOR 1; CYCLIC AMP; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHODIESTERASE IV INHIBITOR; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; XT 611;

ADHERENT CELL; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BONE MARROW CELL; BONE MARROW DEPRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; ENZYME INHIBITION; MITOSIS INHIBITION; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; STEM CELL; STROMA CELL;

EID: 0042931350     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00409-X     Document Type: Article

References (37)

1. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:1995;725-748.
2. Conti M., Nemoz G., Sette C., Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16:1995;370-389.
3. Soderling S.H., Bayuga S.J., Beavo J.A. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl. Acad. Sci. U.S.A. 95:1998;8991-8996.
4. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., Cheng J.B. Isolation and characterization of PDE 9A a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273:1998;15559-15564.
5. Polson J.B., Krzanowski J.J., Szentivanyi A. Inhibition of high affinity cyclic AMP phosphodiesterase and relaxation of canine tracheal smooth muscle. Biochem. Pharmacol. 31:1982;3404-3406.
6. Miyamoto K., Kurita M., Ohmae S., Sakai R., Sanae F., Takagi K. Selective tracheal relaxation and phosphodiesterase-IV inhibition by xanthine derivatives. Eur. J. Pharmacol. 267:1994;317-322.
7. Semmler J., Wachtel H., Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses TNFα production by human mononuclear cells. Int. J. Immunopharmacol. 15:1993;409-413.
8. Miyamoto K., Waki Y., Horita T., Kasugai S., Ohya K. Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem. Pharmacol. 54:1997;613-617.
9. Waki Y., Horita T., Miyamoto K., Ohya K., Kasugai S. Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastogenesis and osteoclastogenesis in culture and its therapeutic effects in rat osteopenia models. Jpn. J. Pharmacol. 79:1999;477-483.
10. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., Dubose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:1997;175-179.
11. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA. 95:1998;3597-3602.
12. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 139:1998;4743-4746.
13. Nagai M., Sato N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem. Biophys. Res. Commun. 257:1999;719-723.
14. Hata K., Kukita T., Akamine A., Kukita A., Kurisu K. Trypsinized osteoclast-like multinucleated cells formed in rat bone marrow cultures efficiently form resorption lacunae on dentine. Bone. 13:1992;139-146.
15. Mano M., Arakawa T., Nakagawa M., Kaneda T., Kaneko H., Yamada T., Miyata K., Kiyomura H., Kumegawa H., Hakeda Y. Prostaglandin E2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through EP4 receptor. Calcif. Tissue Int. 67:2000;85-92.
16. Sawanishi H., Suzuki H., Yamamoto S., Waki Y., Kasugai S., Ohya K., Suzuki N., Miyamoto K., Takagi K. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines. J. Med. Chem. 40:1997;3248-3253.
17. Ly I.A., Mishell R.I. Separation of mouse spleen cells by passage through column of Sephadex G-10. J. Immunol. Methods. 5:1974;239-247.
18. Niida S., Kaku M., Amano H., Yoshida H., Kataoka H., Nishikawa S., Tanne K., Maeda N., Nishikawa S., Kodama H. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190:1999;293-298.
19. Nagai M., Sato N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem. Biophys. Res. Commun. 257:1999;719-723.
20. Waki Y., Miyamoto K., Kasugai S., Ohya K. Osteoporosis-like changes in Walker carcinoma 256-bearing rats, not accompanied with hypercalcemia or parathyroid hormone-related protein production. Jpn. J. Cancer Res. 86:1995;470-476.
21. Udagawa N., Takahashi N., Akatsu T., Sasaki T., Yamaguchi A., Kodama H., Martin T.J., Suda T. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology. 125:1989;1805-1813.
22. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Goto M., Mochizuki S., Tsuda E., Morinaga T., Udagawa N., Takahashi N., Suda T., Higashio K. A novel molecular mechanism modulating osteoclast differentiation and function. Bone. 25:1999;109-113.
23. Lee S.K., Lorenzo J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology. 140:1999;3552-3561.
24. Kanazawa M., Sugimoto T., Kanatani M., Chihara K. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur. J. Endocrinol. 142:2000;661-664.
25. Coleman R.A., Smith W.L., Narumiya S. Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
26. Takahashi N., Yamana H., Yoshiki S., Roodman G.D., Mundy G.R., Jones S.J., Boyde A., Suda T. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow culture. Endocrinology. 122:1988;1373-1382.
27. Tomita M., Li X., Okada Y., Woodiel F.N., Young R.N., Pilbeam C.C., Raisz L.G. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone. 30:2002;159-163.
28. Chenu C., Kurihara N., Mundy G.R., Roodman G.D. Prostaglandin E2 inhibits formation of osteoclast-like cells in long-term human marrow cultures but is not a mediator of the inhibitory effects of transforming growth factor-β J. Bone Miner Res. 5:1990;677-681.
29. Quinn J.M.W., Sabokbar A., Denne M., de Vernejoul M.C., McGee J.O.D., Athanasou N.A. Inhibitory and stimulatory effects of prostaglandins on osteoclast differentiation. Calcif. Tissue Int. 60:1997;63-70.
30. Roodman G.D. Cell biology of the osteoclast. Exp. Hematol. 27:1999;1229-1241.
31. Nicholson G.C., Moseley J.M., Sexton P.M., Mendelsohn F.A., Martin T.J. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J. Clin. Invest. 78:1986;355-360.
32. Lee S.K., Goldring S.R., Lorenzo J.A. Expression of the calcitonin receptor in BMC cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin. Endocrinology. 136:1995;4572-4581.
33. Sotirios T. Parathyroid hormone induces prostaglandin G/H synthase-2 expression by a cyclic adenosine 3′,5′-monophosphate mediated pathway in the murine osteoblastic cell line MC3T3-E1. Endocrinology. 137:1990;5435-5440.
34. Oshima T., Yoshimoto T., Yamamoto S., Kumegawa M., Yokoyama S., Tanabe T. cAMP-dependent induction of fatty acid cyclooxygenase mRNA in mouse osteoblastic cells (MC3T3-E1). J. Biol. Chem. 266:1991;13621-13626.
35. Wachtel H. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3′:5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology. 77:1982;309-316.
36. Howell R.E., Muehsam W.T., Kinnier W.J. Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci. 46:1990;563-568.
37. 3H ]rolipram binding activity and their relationship to emetic behavior in the ferret J. Med. Chem. 39:1996;120-125.